Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTT7PJU)

• DTT Name: Janus kinase 3 (JAK-3) DTT Info
• Gene Name: JAK3

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abrocitinib	DM8J29L	Atopic dermatitis	EA80	Approved	[1]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Approved	[2]
Ritlecitinib	DMYKNME	Alopecia areata	ED70.2	Approved	[3]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[4]

12 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[5]
VX-509	DM2U3MX	Rheumatoid arthritis	FA20	Phase 2/3	[6]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[7]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[8]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[3]
TD-8236	DMTOMJN	Asthma	CA23	Phase 2	[9]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[10]
AZD4604	DMP3CSV	Asthma	CA23	Phase 1	[11]
GDC-0214	DMCNSII	Asthma	CA23	Phase 1	[12]
KN-002	DMK8FHB	Severe asthma	CA23	Phase 1	[13]
PF-07295324	DMBE63K	Atopic dermatitis	EA80	Phase 1	[14]
SNA-125	DM8L1GJ	Atopic dermatitis	EA80	Phase 1	[3]

65 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,2,4-triazolo[1,5a]pyridine derivative 1	DMIUPSA	N. A.	N. A.	Patented	[15]
Aminooxazole carboxamide derivative 1	DMDHGPN	N. A.	N. A.	Patented	[16]
Aminotriazolopyridine derivative 1	DMW2LZ0	N. A.	N. A.	Patented	[15]
Benzimidazole derivative 5	DMWOJLX	N. A.	N. A.	Patented	[16]
Benzimidazole derivative 7	DMDK4RI	N. A.	N. A.	Patented	[15]
Bis-aminopyrimidine derivative 1	DMQL34C	N. A.	N. A.	Patented	[15]
Bis-aminopyrimidine derivative 2	DMJXNO1	N. A.	N. A.	Patented	[15]
Bis-aminopyrimidine derivative 3	DMUNSYX	N. A.	N. A.	Patented	[15]
Bis-aminopyrimidine derivative 4	DMO1ZIG	N. A.	N. A.	Patented	[15]
Five-and-six-membered heterocyclic compound 1	DM7SK5Q	N. A.	N. A.	Patented	[16]
Imidazopyridazine derivative 1	DMEY6L8	N. A.	N. A.	Patented	[15]
Imidazopyridazine derivative 2	DMZORKY	N. A.	N. A.	Patented	[15]
Imidazopyridine derivative 4	DMP2AXV	N. A.	N. A.	Patented	[15]
Imidazo[4,5-c]pyridine derivative 1	DM4KBZQ	N. A.	N. A.	Patented	[15]
Imidazo[4,5-c]pyridine derivative 2	DMFDRJT	N. A.	N. A.	Patented	[15]
Isoxazole derivative 1	DMUMPZX	N. A.	N. A.	Patented	[16]
Isoxazole derivative 2	DMT842O	N. A.	N. A.	Patented	[16]
N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1	DM0OMAL	N. A.	N. A.	Patented	[15]
N-methylmethanesulfonamide derivative 1	DMIVK7D	N. A.	N. A.	Patented	[16]
PMID27774822-Compound-Figure10Example1	DMCTXPQ	N. A.	N. A.	Patented	[16]
PMID27774822-Compound-Figure10Example19	DMNXYZP	N. A.	N. A.	Patented	[16]
PMID27774822-Compound-Figure11Example5	DMAHFXV	N. A.	N. A.	Patented	[16]
PMID27774822-Compound-Figure1Example20	DMCL19N	N. A.	N. A.	Patented	[16]
PMID27774822-Compound-Figure2Example1-1left	DM86M7D	N. A.	N. A.	Patented	[16]
PMID27774822-Compound-Figure2Example1-1right	DM2YPLF	N. A.	N. A.	Patented	[16]
PMID27774822-Compound-Figure2Example4-3	DMEHIS4	N. A.	N. A.	Patented	[16]
PMID27774822-Compound-Figure6Example2	DMCD19T	N. A.	N. A.	Patented	[16]
PMID27774822-Compound-Figure6Example3	DM3FY85	N. A.	N. A.	Patented	[16]
PMID27774822-Compound-Figure8Example5	DMRHZF3	N. A.	N. A.	Patented	[16]
PMID27774824-Compound-Figure11Example1up	DMH1W8F	N. A.	N. A.	Patented	[15]
PMID27774824-Compound-Figure12Example1	DMAGKNJ	N. A.	N. A.	Patented	[15]
PMID27774824-Compound-Figure12Example10	DMYOSIA	N. A.	N. A.	Patented	[15]
PMID27774824-Compound-Figure12Example61	DMNIZD7	N. A.	N. A.	Patented	[15]
PMID27774824-Compound-Figure2Example4	DMQHYMJ	N. A.	N. A.	Patented	[15]
PMID27774824-Compound-Figure3Example18	DMYZ6XQ	N. A.	N. A.	Patented	[15]
PMID27774824-Compound-Figure3Example7	DMXDOGK	N. A.	N. A.	Patented	[15]
PMID27774824-Compound-Figure5Example13	DMDZKXC	N. A.	N. A.	Patented	[15]
PMID27774824-Compound-Figure6Example12	DM1CM7S	N. A.	N. A.	Patented	[15]
PMID27774824-Compound-Figure9Example2down	DMXAV42	N. A.	N. A.	Patented	[15]
PMID27774824-Compound-Figure9Example2up	DME3TMS	N. A.	N. A.	Patented	[15]
Pyrazolopyridine derivative 1	DMY03RZ	N. A.	N. A.	Patented	[16]
Pyrazolopyridine derivative 2	DMCJVLR	N. A.	N. A.	Patented	[16]
Pyrazolopyridine derivative 3	DM2VQ4P	N. A.	N. A.	Patented	[16]
Pyrazolopyridine derivative 4	DMX7RWV	N. A.	N. A.	Patented	[16]
Pyrazolopyridine derivative 6	DM5OH8D	N. A.	N. A.	Patented	[15]
Pyrazolopyridine derivative 7	DMCTQ9O	N. A.	N. A.	Patented	[15]
Pyrazolo[4,3-c]pyridine derivative 2	DMCDFLQ	N. A.	N. A.	Patented	[15]
Pyrimidopyridazinone derivative 2	DMD1RT0	N. A.	N. A.	Patented	[15]
Pyrrole six-membered heteroaryl ring derivative 1	DM1A0VB	N. A.	N. A.	Patented	[16]
Pyrrolo-pyrazine derivative 1	DMP8I02	N. A.	N. A.	Patented	[16]
Pyrrolo-pyrazine derivative 2	DMO9Q8J	N. A.	N. A.	Patented	[16]
Pyrrolo-pyrazine derivative 3	DMLM6DT	N. A.	N. A.	Patented	[16]
Pyrrolo-pyrazine derivative 4	DMD1S92	N. A.	N. A.	Patented	[16]
Pyrrolo-pyridine derivative 3	DMSNQEJ	N. A.	N. A.	Patented	[16]
Pyrrolo[2,3-d]pyrimidine derivative 6	DM3D1L6	N. A.	N. A.	Patented	[16]
Pyrrolo[2,3-d]pyrimidine derivative 7	DM30Y8M	N. A.	N. A.	Patented	[16]
Pyrrolo[2,3-d]pyrimidine derivative 8	DMAW6KU	N. A.	N. A.	Patented	[16]
Ruxolitinib derivative 2	DMSJWZ3	N. A.	N. A.	Patented	[15]
Tricyclic compound 1	DMLBR4F	N. A.	N. A.	Patented	[15]
Tricyclic compound 11	DMJAZ7D	N. A.	N. A.	Patented	[16]
Tricyclic compound 2	DMJAWOI	N. A.	N. A.	Patented	[15]
Tricyclic heterocycle derivative 1	DMXLJH4	N. A.	N. A.	Patented	[16]
Tricyclic heterocycle derivative 2	DM1W02D	N. A.	N. A.	Patented	[15]
Tricyclic heterocycle derivative 5	DMG1ESV	N. A.	N. A.	Patented	[16]
Tricyclic pyrrolopyridine compound 1	DMFIXW4	N. A.	N. A.	Patented	[16]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AG490	DM3WKO5	Multiple myeloma	2A83	Terminated	[17]
PNU156804	DM23ZHN	Renal transplantation	NE84	Terminated	[18]
R348	DM12EYR	Psoriasis vulgaris	EA90	Terminated	[19]

12 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
6-o-tolylquinazolin-2-amine	DM4TX9O	Discovery agent	N.A.	Investigative	[20]
AD-412	DMJMCDP	Autoimmune diabetes	5A10	Investigative	[5]
Atropisomer 1	DML3R5Z	Discovery agent	N.A.	Investigative	[21]
CMP-6	DM241YW	Discovery agent	N.A.	Investigative	[22]
NC1153	DM6XGFE	Renal transplantation	NE84	Investigative	[17]
PF-956980	DMIUZSR	Inflammation	1A00-CA43.1	Investigative	[5]
PMID15546730C2	DMOPUIH	Discovery agent	N.A.	Investigative	[23]
PMID21493067C1d	DMFUQIT	Discovery agent	N.A.	Investigative	[24]
PMID24359159C19a	DM26JYS	Discovery agent	N.A.	Investigative	[25]
VX-467	DM4Q5DO	Inflammation	1A00-CA43.1	Investigative	[5]
WHI-P154	DMYHWS1	Diffuse large B-cell lymphoma	2A81	Investigative	[26]
ZM-39923	DMTMVYH	Discovery agent	N.A.	Investigative	[27]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 213871.
• [2] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 208712.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
• [6] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [7] Clinical pipeline report, company report or official report of Aclaris Therapeutics.
• [8] ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [10] The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
• [11] Clinical pipeline report, company report or official report of AstraZeneca
• [12] Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A?randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021 Sep;148(3):783-789.
• [13] Clinical pipeline report, company report or official report of Kinaset Therapeutics
• [14] Clinical pipeline report, company report or official report of Pfzer
• [15] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
• [16] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
• [17] Immunotherapy for De Novo renal transplantation: what's in the pipeline Drugs. 2006;66(13):1665-84.
• [18] Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15;99(2):680-9.
• [19] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [20] Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86.
• [21] Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41.
• [22] Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23.
• [23] Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
• [24] In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61.
• [25] Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58.
• [26] The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
• [27] Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9.